Tianjin Ringpu Bio-technology Co., Ltd.
Ringpu
Ringpu Biology (Tianjin Ringpu Bio-technology Co., Ltd.) is China's preeminent listed animal health manufacturer and the only Asian-headquartered company in this global Top 10 ranking. Founded in 1998 and headquartered in Tianjin, China, Ringpu generated CNY 3.398 billion (~USD 470 million) in 2025 revenue (up 7.72%), with its pet health segment surging 24.39% to CNY 858 million. Ringpu's defining competitive advantage is its "API-to-endpoint" closed ecosystem: 11 mega-scale production bases housing 94 fully automated production lines with 500+ product approvals, vertically integrated through its affiliate Zhongrui Supply Chain and sister company Ringpai Pet Hospital network directly serving over 14,000 veterinary endpoints nationwide—eliminating distribution layers and maximizing factory utilization.
Strengths:
• Unmatched Manufacturing Scale in Asia: 11 mega-scale production bases, 94 automated production lines, and 500+ veterinary drug approvals—the largest animal health manufacturing footprint in China
• API-to-Endpoint Vertical Integration: In-house API synthesis and biological fermentation eliminates upstream supply chain dependency, enabling aggressive pricing while maintaining margins
• Pet Segment Hypergrowth: CNY 858 million in 2025 companion animal revenue (up 24.39% YoY), driven by domestic feline triple vaccines, canine multivalent vaccines, and long-acting parasiticides
• Direct-to-Clinic Ecosystem: Ringpai Pet Hospital network and Zhongrui Supply Chain collectively serve 14,000+ veterinary endpoints, creating a closed loop from factory to patient
• Regulatory Moat in China: 500+ domestic product approvals create a formidable barrier to entry for foreign competitors seeking Chinese market access
Weaknesses:
• Minimal International Presence: Revenue remains overwhelmingly China-dependent with limited regulatory approvals or brand recognition in North American and European markets
• Brand Premium Gap: Products are positioned as cost-competitive alternatives rather than premium-priced innovations, limiting margin potential in high-value therapeutic categories
• Innovation Depth: Pipeline remains concentrated on vaccines and generics; the company has yet to develop proprietary novel chemical entities or biologics comparable to Western competitorsRead More ▼Show Less ▲
Strengths:
• Unmatched Manufacturing Scale in Asia: 11 mega-scale production bases, 94 automated production lines, and 500+ veterinary drug approvals—the largest animal health manufacturing footprint in China
• API-to-Endpoint Vertical Integration: In-house API synthesis and biological fermentation eliminates upstream supply chain dependency, enabling aggressive pricing while maintaining margins
• Pet Segment Hypergrowth: CNY 858 million in 2025 companion animal revenue (up 24.39% YoY), driven by domestic feline triple vaccines, canine multivalent vaccines, and long-acting parasiticides
• Direct-to-Clinic Ecosystem: Ringpai Pet Hospital network and Zhongrui Supply Chain collectively serve 14,000+ veterinary endpoints, creating a closed loop from factory to patient
• Regulatory Moat in China: 500+ domestic product approvals create a formidable barrier to entry for foreign competitors seeking Chinese market access
Weaknesses:
• Minimal International Presence: Revenue remains overwhelmingly China-dependent with limited regulatory approvals or brand recognition in North American and European markets
• Brand Premium Gap: Products are positioned as cost-competitive alternatives rather than premium-priced innovations, limiting margin potential in high-value therapeutic categories
• Innovation Depth: Pipeline remains concentrated on vaccines and generics; the company has yet to develop proprietary novel chemical entities or biologics comparable to Western competitors
Listed market data
300119 · SZSE · weeklyHistory →- Market cap
- $1.1 B
- Share price
- ≈ CNY 2.40
- 1Y change
- -25.0%
- Recent change
- +0.9%
- IPO price
- +11.8%
- Revenue (TTM)
- CNY$3.4 B (~USD$470 M, 2025)
10-22 → 10-23
CNY 60.00 · from 2010-09-17
Financial history
Full market history- 2026-10CNY 16.17$1.1 B-3.5%
- 2026-09CNY 16.76$1.2 B-3.1%
- 2026-08CNY 17.30$1.2 B+1.6%
- 2026-07CNY 17.02$1.2 B+17.9%
- 2026-06CNY 14.43$996 M-10.6%
- 2026-05CNY 16.14$1.1 B-10.3%
- 2026-04CNY 18.00$1.2 B+3.3%
- 2026-03CNY 17.43$1.2 B-11.5%
- 2026-02CNY 19.69$1.4 B-1.2%
- 2026-01CNY 19.92$1.4 B+6.1%
- 2025-12CNY 18.77$1.3 B-5.4%
- 2025-11CNY 19.85$1.4 B—
Its pet health segment achieved CNY 858 million in 2025 revenue up 24.39% YoY, driven by domestic feline triple vaccines, canine multivalent vaccines, and long-acting parasiticides. Most critically, Ringpu has built an unparalleled "manufacturing-to-endpoint" closed ecosystem in China: through its affiliate Zhongrui Supply Chain and sister company Ringpai Pet Hospital network, it directly serves over 14,000 veterinary endpoints nationwide—eliminating layers of distributors and maximizing factory utilization.
• Pet Vaccines: feline triple / canine quadrivalent
• Parasiticides: long-acting oral/topical formulations
• Anti-infectives & Anti-inflammatories
• Biologics: avian/swine vaccines
• Diagnostic Kits & Devices
• Feed Additives & Nutritional Supplements
• Disinfectants
Quick Facts
Headquarters
Tianjin, China
Founded
1998
Employees
1,000+
Revenue
CNY$3.4 B (~USD$470 M, 2025)
Market cap
$1.1 B
Factories
11 mega-scale production bases with 94 production lines
Presence
China market, expanding internationally
Listing
SZSE: 300119
Categories
10 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website SZSE: 300119 , Ringpu Official Website
Shenzhen Stock Exchange — Ringpu (300119)
Wikipedia — Ringpu Biology